title: Targeted products yield most promising results.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Klem
authors.forename: Stanton R
authors.initials: SR
authors.lastname: Mehr
authors.forename: Marj
authors.initials: M
authors.lastname: Pestil Zimmerman
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D005260:Female; D005544:Forecasting; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D057285:Precision Medicine; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D013449:Sulfonamides / Q000627:therapeutic use; D014481:United States; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib